 |
|
|
|
 |
|
|
| Article 1 to 10 out of 18 concerning Biotage AB
|
-
QIAGEN Acquires Biosystems Business from Biotage
(06 Oct 2008)
Transaction adds fundamental assay technology for high-resolution sequence detection and quantification of genetic variations
QIAGEN N.V. announced that it has acquired all assets related to the Biosystems business from Biotage AB, a publicly listed developer, manufacturer and distributor of products for genetic analysis and medicinal chemistry headquartered in Uppsala, ...
-
Biotage AB and McMaster University sign two year extension to Molecular Imaging Development Agreement
(06 Mar 2008)
Biotage AB and McMaster University sign a two year extension to Molecular Imaging Development Agreement. McMaster University has successfully completed the first year research agreement, with a key journal publication and several technical ...
-
Biotage AB Increases Focus on Environmental Market Segments
(21 Feb 2008)
Biotage AB announced plans to increase its focus on growing business opportunities in the environmental analysis business. The strategy includes redeployed marketing and sales resources along with new product development for specific application ...
-
Biotage open up new business area: Molecular Imaging
(21 Jun 2007)
Molecular Imaging is an emerging market that is playing an important role to the ongoing worldwide efforts at improving health care and cost saving in the Pharma Industry. Biotage entered into a Molecular Imaging collaboration with McMaster ...
-
Biotage AB and Shanghai Chempartner Co., Ltd. sign multi-instrument deal
(27 Apr 2007)
Shanghai Chempartner Co., Ltd., a Chinese Contract Research Organizations (CRO), has invested in Biotage SP automated flash instruments and Initiator microwave synthesizers with delivery scheduled over the next 12 months. This is Biotages's largest ...
-
Biotage AB and McMaster University sign joint agreement to develop new chemistry platform
(28 Feb 2007)
Biotage AB and McMaster University signed a joint agreement to develop a new chemistry platform to speed the production of molecular imaging and therapy agents. As part of the agreement, Biotage will provide funding and instruments. The McMaster ...
-
Biotage Makes a Change in Top Management after Business Area President resigns
(02 Mar 2006)
The life science company Biotage, listed on the O-list of the Stockholm stock exchange, makes a change in its top management. David Patteson, President of the business area Discovery Chemistry has decided to seek new challenges elsewhere. He will ...
-
Torben Jörgensen New CEO at Biotage
(13 Feb 2006)
The life science company Biotage makes a further strategic move to integrate its acquired businesses and to optimize the product portfolio, with the intention to focus on organic growth. As a part of this process, Torben Jörgensen will succeed Jeff ...
-
Biotage AB Acquires Separtis Holding AG for 1.4M Euros (13M SEK) and Completes EU Distribution Consolidation
(11 Oct 2005)
Biotage has acquired Separtis Holding AG, the Swiss, German and Austrian distributor for many Biotage products, formerly the Argonaut Technologies consumable product range. Under the terms of the agreement Biotage will retain all current Separtis ...
-
Resolutions at the Annual General Meeting in Biotage AB
(02 May 2005)
At the Annual General Meeting held in Biotage AB on April 27, 2005, the following resolutions were passed, among others. Appropriation of the company's resultThe General Meeting resolved, in accordance with the proposal by the Board of Directors and ...
|
|
|
|
|
Top
